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Introduction: Ankylosing spondylitis (AS) is associated with an increased incidence of vertebral fractures (VFs);
however the actual incidence and predictors of morphometric VFs are unknown. The present study examined the
incidence and predictors of new VFs in a large AS cohort.
Methods: In total, 298 AS patients who fulfilled the modified New York criteria were enrolled and spinal radiographs
were evaluated biennially. Clinical and laboratory data and radiographic progression were assessed according to the
Bath AS Disease Activity Index, erythrocyte sedimentation rate, C-reactive protein (CRP), and the Stoke AS spine score
(SASSS). VF was defined according to the Genant criteria. The incidence of VFs at 2 and 4 years was evaluated using
the Kaplan-Meier method. The age-specific standardized prevalence ratio (SPR) for AS patients in comparison with
the general population was calculated.
Results: Of 298 patients, 31 (10.8%) had previous VFs at baseline. A total of 30 new VFs occurred in 26 patients over
4 years. The incidence of morphometric VFs was 4.7% at 2 years and 13.6% at 4 years. Multivariate logistic regression
analysis showed that previous VFs at baseline and increased CRP levels at 2 years were predictors of new VFs
(odds ratio (OR) =12.8, 95% confidence interval (CI) = 3.6-45.3 and OR = 5.4, 95% CI = 1.4–15.9). The age-specific
specific standardized prevalence ratio of morphometric VFs in AS was 3.3 (95% CI 2.1–4.5).
Conclusions: The incidence of morphometric VFs increased in AS. Previous VFs and increased CRP levels predicted
future VFs. Further studies are needed to identify the effects of treatment interventions on the prevention of new VFs.Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory
disease that mainly affects the sacroiliac joint, vertebrae,
and spinal ligaments. The disease typically affects male
patients and usually becomes apparent between 20 and
30 years of age [1]. Bone is the target in AS and chronic
inflammation leads to a wide range of changes, particu-
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unless otherwise stated.Bone complications in AS include new bone formation
in the form of syndesmophytes and erosions, generalized
osteoporosis, and vertebral fractures (VFs) [2,3]. Earlier
studies indicate an increased risk of osteoporosis and
morphometric VFs in AS. The prevalence of osteopor-
osis is 19 to 61% [4] and the estimated prevalence of
VFs varies from 9.5% to 32.4% [2,5-8]. These differences
may be associated with differences in recruited patients.
The prevalence of VFs is high in AS; however, the
diagnosis of VFs is difficult. Only one in three or one in
four VFs come to clinical attention, with a typical symp-
tom being back pain [9]. Because back pain is common
is AS, misdiagnosis is possible. Therefore, there is a dis-
crepancy between the prevalence of clinical VFs and
morphometric VFs. To date, studies comparing the rela-
tive risk of VFs among AS patients and the general
population have focused on clinical VFs [6,10]. Althoughd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tients suffer only mild back pain, morphometric VFs are
associated with a poor quality of life and impaired phys-
ical function [11]. Because post-fracture wedging of the
vertebrae can contribute to hyperkyphosis and neuro-
logic complications [12], it is important to identify the
predictors of morphometric VFs if we are to effectively
manage AS patients.
Previous studies report the prevalence of morphomet-
ric VFs on x-ray evaluation or fracture vertebral assess-
ment; however, the actual incidence is unknown. One
study reported the incidence of VFs, but only investi-
gated clinical VFs [6]. Therefore, the actual incidence of
morphometric VFs in AS remains unclear. The objec-
tives of this study were to examine the incidence of mor-
phometric VFs on x-ray evaluation in AS patients and to
identify the risk factors associated with new VFs.
Methods
Patients
The study enrolled 298 patients (237 men and 61
women) with AS who fulfilled the modified New York
criteria for the classification of AS [13] and who pre-
sented consecutively between January 2007 and February
2013. This observational cohort study examined pelvis
and lumbar spinal radiographs every 2 years to assess
structural progression. Patients at two participating cen-
ters in South Korea, Seoul Saint Mary’s hospital and
Incheon Saint Mary’s hospital, were enrolled between
January 2007 and February 2011. The participants’ writ-
ten consent was obtained according to the Declaration of
Helsinki. Exclusion criteria included psoriasis, inflamma-
tory bowel disease, reactive arthritis, thyroid or parathy-
roid disorders, and chronic renal or liver disease. Patients
not evaluated at the time of radiography (±3 months)
were excluded. This study was approved by the ethics com-
mittee of the Seoul St. Mary’s hospital (XC13RIMI0129K)
and the Incheon St. Mary’s Hospital, Catholic University of
Korea (XC13RIMI0129O).
Clinical data
Disease activity at baseline and at 2 years and 4 years
was assessed using the Bath AS disease activity index
(BASDAI) and laboratory data (erythrocyte sedimentation
rate (ESR) and C-reactive protein (CRP) levels, measured
every 6 months for 2 or 4 years). Demographic data in-
cluded age, gender, age at AS diagnosis, disease duration, a
history of uveitis, peripheral arthritis, enthesitis, a family
history of AS, and the presence of HLA-B27.
Vertebral fracture assessment
VFs were assessed on lateral radiographs of the lumbar
spine (vertebrae T12 to L4) using the standardized semi-
quantitative method described by Genant et al. [14]. Thevertebrae were assigned a severity grade based on the
visually apparent degree of vertebral height loss. Each
vertebra was assigned a grade based on the Genant
semiquantitative scale (0 to 3). Grade 0 is normal; grade
1 (mild) represents a reduction in vertebral height of 20
to 25%; grade 2 (moderate) represents a reduction of 25
to 40%; and grade 3 (severe) represents a reduction of
over 40%. VFs were defined as a reduction in vertebral
height ≥20% [14]. Grading was performed by two experi-
enced investigators (KYK and IJK). There were few dis-
crepancies and the two investigators reached a consensus.
The inter-observer variability was calculated using Cohen’s
kappa value (kappa = 0.81). If a 2-year radiograph was
missing and the 4-year radiograph showed no evidence of
fracture, it was assumed that there was no fracture at
2 years.
Radiographic scoring
Radiographs of the lumbar spine and pelvis were ob-
tained at baseline and after 2 years and 4 years of follow
up. Sacroiliitis was assessed by viewing images of the
sacroiliac joint and was graded according to the New
York criteria [13]. The reader was blinded to the clinical
details of the patients. Radiographic changes related to
AS in the lumbar spine were assessed using the Stokes
ankylosing spondylitis spine score (SASSS). To obtain
the SASSS, the anterior and posterior vertebrae of the
lumbar (T12 lower to S1 upper) spinal segments were
scored (0 to 3 points each, where 0 = normal, 1 = erosion,
sclerosis, or squaring; 2 = syndesmophyte formation; and
3 = a bridging syndesmophyte) [15]. A change ≥2 SASSS
units in 2 years was defined as significant; such patients
were placed in the SASSS progression group.
Treatment
We also investigated medications such as non-steroidal
anti-inflammatory drugs (NSAIDs), sulfasalazine, metho-
trexate (MTX), tumor necrosis factor (TNF) inhibitors,
calcium, and bisphosphonate. All patients treated with
TNF inhibitors received the drug throughout the study
period. Patients who were on other medications for
more than 50% of the study period were considered sus-
tained users. For patients treated with TNF inhibitors,
baseline radiographs were performed at the beginning of
TNF inhibitor therapy.
Statistical analysis
Statistical analyses were performed using PASW statis-
tics 18. Data were expressed as the mean ± SD. Normally
distributed demographic and radiologic variables were
compared using the independent t-test and non-normally
distributed variables were compared using the Mann-
Whitney U-test. The Chi-squared test was used to com-
pare categorical variables. Multivariate logistic regression
Table 1 Baseline characteristics of 298 patients with
ankylosing spondylitis




Age (years) 33.9 ± 10.9
Age at diagnosis (years) 30.1 ± 10.8
Disease duration (years) 3.8 ± 5.1
Family history of AS 27 (9.1)
HLA-B27-positive1 244 (92.1)
Back pain 293 (98.7)
History of peripheral arthritis 190 (63.8)
History of enthesitis 71 (23.8)
History of uveitis 87 (29.7)
BASDAI, score 5.4 ± 1.8
Sacroiliitis grade
Right 3.1 ± 0.7
Left 3.1 ± 0.7
Mean sacroiliitis grade 3.1 ± 0.7
SASSS, score (range) 8.6 ± 15.9 (0 to 69)
ESR, mm/h 28.6 ± 25.8
CRP, mg/L 1.7 ± 3.1
Patients on NSAIDs 245 (82.2)
Patients on sulfasalazine 141 (47.3)
Patients on MTX 86 (29.1)
Patients on TNF inhibitors 118 (39.6)
Patients on calcium 22 (11.1)
Patients on bisphosphonate 8 (2.7)
1Confirmed in 265 patients. AS, ankylosing spondylitis; BASDAI, Bath AS
disease activity index; SASSS, Stokes ankylosing spondylitis spine score;
NSAIDs, non-steroidal anti-inflammatory drugs; MTX, methotrexate; TNF,
tumor necrosis factor.
Figure 1 Incidence of vertebral fractures (VFs) over 4 years. Thirty VFs
study period. (A) The incidence of VFs was 4.7% at 2 years and 13.6% at 4
vertebra L1: 24 VFs were Genant grade 1 and 6 VFs were grade 2. Error bar
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tween variables and the incidence of new VFs. All variables
with a P-value <0.10 in the univariate analysis were incor-
porated as explanatory variables. The cumulative incidence
of new VFs over time was estimated using the Kaplan-
Meier method. The log-rank test was used to compare the
incidence rate according to different variables.
When comparing the prevalence of radiographic mor-
phometric VFs in AS patients with that in the Korean
general population [16], all AS patients under 40 years
of age were excluded because all members of the gen-
eral population group were ≥40 years old. We applied
the age-specific prevalence of morphometric VF in the
Korean general population study to the age distribution
of our AS cohort, and calculated an age-standardized
prevalence ratio (SPR) and its 95% CI. All tests were
two tailed and a P-value <0.05 was considered statistically
significant.
Results
Table 1 shows the baseline characteristics of the 298 AS
patients. The mean age of the patients was 33 ± 11 years,
79.5% were male, and 92.1% were HLA-B27-positive.
The mean disease duration was 3.8 ± 5.1 years and the
mean age at diagnosis was 30 ± 11 years. The mean
BASDAI score was 5.3 ± 1.8, the mean grade of sacroi-
liitis was 3.1 ± 0.7, and the mean SASSS score was
8.6 ± 15.9. The mean baseline ESR was 28.6 ± 25.8 mm/h
and the mean CRP was 1.7 ± 3.1 mg/L. Of the 298 patients
included in the study, 118 (39.6%) received TNF inhibitors.
The clinical and radiological parameters and treatments
are shown in Table 1.
Vertebral fractures
Of the 298 patients, 31 (10.8%) had previous VFs at base-
line. The 298 patients were observed for a total of 852of 298 patients were observed for a total of 852 person-years over the
years. (B) This resulted in a total of 30 fractures, most commonly at
s represent the mean (SD).
Table 2 Comparison of characteristics of patients with






Mean ± SD or number (%) (n = 272) (n = 26)
Male 215 (79) 22 (85) 0.617
Age, years 33.8 ± 10.9 35.2 ± 12.2 0.526
Age at diagnosis, years 30.0 ± 10.6 31.6 ± 11.9 0.459
Disease duration, years 3.8 ± 5.1 3.6 ± 5.2 0.847
Family history of AS 24 (9) 3 (12) 0.717
HLA-B27-positive1 226 (93) 18 (82) 0.083
Back pain 267 (98.5) 26 (100) 1.000
History of peripheral arthritis 176 (65) 14 (54) 0.290
History of enthesitis 62 (23) 9 (35) 0.226
History of uveitis 85 (32) 2 (8) 0.012
Presence of baseline VF 22 (8) 9 (35) <0.001
Baseline BASDAI score 5.5 ± 1.8 5.2 ± 1.7 0.726
Baseline mean sacroiliitis grade 3.1 ± 0.7 3.1 ± 0.9 0.945
Baseline SASSS score 15.8 ± 1.0 13.1 ± 17.8 0.138
Significant SASSS progression2 47 (18) 9 (39) 0.026
Baseline ESR, mm/h 26.2 ± 1.6 24.4 ± 20.6 0.397
Baseline CRP, mg/L 1.8 ± 3.2 1.0 ± 1.3 0.251
Increase in ESR at 2 years 153 (56) 12 (46) 0.542
Increase in CRP at 2 years 50 (22) 9 (47) 0.020
Patients on NSAIDs 223 (82) 22 (85) 1.000
Patients on sulfasalazine 124 (46) 12 (46) 1.000
Patients on MTX 82 (30) 4 (15) 0.119
Patients on TNF inhibitors 112 (41) 6 (23) 0.093
Patients on calcium 31 (12) 2 (8) 0.751
Patients on bisphosphonate 8 (3) 0 (0) 0.475
1Confirmed in 265 patients; 2change ≥2 SASSS units over the first 2 years
post-baseline. VF, vertebral fracture; AS, ankylosing spondylitis; ESR,
erythrocyte sedimentation rate; CRP, C-reactive protein; BASDAI, Bath AS
disease activity index; SASSS, Stokes ankylosing spondylitis spine score;
NSAIDs, Non-steroidal anti-inflammatory drugs; MTX, Methotrexate; TNF,
tumor necrosis factor.
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data were available for 287 (96.3%) patients at 2 years
and for 131 (40.6%) patients at 4 years. Thirty new VFs
were identified in 26 (8.7%) patients. Figure 1A shows
that the incidence of VFs was 4.7% at 2 years and
13.6% at 4 years. The most common location of a new
VF was L1 (40%). Twenty-three patients had one VF,
two had two VFs, and one had three VFs. In total, 24
grade-1 fractures and 6 grade-2 fractures were detected;
no grade-3 fractures were found (Figure 1B). Nine pa-
tients among the 26 patients with new VFs experienced
SASSS progression over the first 2 years. In six out of
nine patients, the incident vertebral fractures occurred
at same location as SASSS progression.
Comparison of the characteristics of patients with and
without incident VFs
A comparison of the characteristics of patients with and
without new VFs revealed that those with new VFs were
less likely to be HLA-B27-positive or to have uveitis
(P = 0.083 and 0.012, respectively) as shown in Table 2.
Significant increases in the SASSS score and CRP levels
over the first 2 years were more common in AS patients
with new VFs than in those without (P = 0.026 and 0.020,
respectively). The prevalence of previous VFs at baseline
was significantly higher in patients with new VFs than in
those without (P <0.001).
The use of TNF inhibitors was more common in pa-
tients without new VFs than in those with new VFs;
however, the difference was not statistically significant.
The number of patients treated with NSAIDs, DMARDs,
or calcium and bisphosphonates did not differ between
the two groups.
Figure 2 shows the difference of the incidence of new
VFs according to the previous VFs at baseline and the
increase in CRP levels at 2 years post-baseline. When
the patients had a previous VF at baseline, the hazards
ratio (HR) for VF incidence increased to 6.7 (95% CI = 2.3
to 19.2) at 2 years and to 5.5 (95% CI = 2.5 to 12.4) at
4 years. Additionally, when the CRP level at 2 years was
higher than that at baseline, the HR for VF incidence in-
creased to 4.3 (95% CI = 1.5 to 12.5) at 2 years and to 3.0
(95% CI = 1.2 to 7.4) at 4 years.
Risk factors associated with new VF incidence
Multivariate logistic regression analysis showed that the
incidence of new VFs was independently associated with
previous VFs at baseline and with increased CRP levels
at 2 years, with odds ratios (OR) of 12.8 (95% CI 3.6 to
45.3) and 5.4 (95% CI 1.4 to 15.9), respectively (Table 3).
Subgroup analysis showed that the increase in CRP
levels was independently associated with the develop-
ment of new VFs in patients with no previous VFs at
baseline (OR = 4.8, 95% CI = 1.4 to 15.9).Table 4 shows the age-specific SPR for morphometric
VFs in AS patients compared with the morphometric
VFs expected in the Korean general population [16]. There
was a significant increase in the risk of morphometric VFs
among AS patients aged over 40 years (standardized Preva-
lence rate (SPR) = 3.3, 95% CI = 2.06 to 4.54).
Discussion
This is a first study to evaluate the incidence of morpho-
metric VFs in AS patients and to identify the risk factors
associated with new VFs. The results show that AS pa-
tients have an increased risk ratio of morphometric VFs
compared with the general population. In this study,
using radiographs, the incidence of morphometric VFs was
Figure 2 Comparisons of incidence of morphometric vertebral fractures (VFs). (A) The risk of VF was significantly increased in patients with
previous VFs at baseline compared with those without. (B) The risk of occurrence of new VFs at 2 years and 4 years was higher in patients with
an increase in C-reactive protein (CRP) levels at 2 years post-baseline than in patients with a reduction.
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risk of morphometric VFs was about three times higher
than that in the general population. Previous studies report
an increased prevalence of clinical VFs in AS patients com-
pared with the general population, which is consistent with
the results reported herein [6,10].
The increased risk for VF in AS patients is due to
biomechanical changes in the material and structural
components of the spine and to osteoimmunology [17].
Radiographic progression, such as syndesmophyte forma-
tion and vertebral bridging, is associated with a reduction
in spinal flexibility. This increased rigidity means that a
simple fall or other minor trauma can result in VFs [18].
Another explanation for the increased risk of VFs in AS is
low bone mineral density (BMD). Reduced BMD is found
in patients with early disease, independently of spinal mo-
bility and exercise levels [19]. Bone loss is associated with
VFs in AS patients [5,7]. It is possible that early trabecular
bone loss in the spine increases the risk of fracture, and
that heterogeneous bone stiffness increases the risk [17].
Both rheumatoid arthritis (RA) and AS are associated with
low BMD and fractures [20].
To date, several studies have examined the prevalence of
morphometric VF in AS and the associated risk factors.Table 3 Multivariate analysis of risk factors associated with n
Variable Total AS patients
(n = 298)
Odds ratio 95% CI P
TNF inhibitor




CRP increase 5.4 1.7 to 17.7
AS, ankylosing spondylitis; TNF, tumor necrosis factor; SASSS, Stokes ankylosing spoKnown risk factors include male gender, age, low BMD,
disease duration, high levels of disease activity, and periph-
eral joint involvement [2,3,5-7,17,21]. However, until now,
no studies have identified factors that predict the incidence
of new VFs in AS patients. The present study shows for
the first time that previous VFs and elevated CRP levels are
risk factors for occurrence of new VFs.
Only 30% of VFs receive clinical attention. Despite this,
patients with a VF are at increased risk of a future fracture
[22]. Once an initial VF is sustained, the risk of a subse-
quent VF increases significantly. This phenomenon has
been termed the vertebral fracture cascade. The mecha-
nisms underlying this fracture cascade are not fully under-
stood, creating uncertainty regarding the prevention of
further fractures [23]. In patients with postmenopausal
osteoporosis, the strongest predictor of a future VF is a
prior VF. Gehlach et al. showed that previous VFs were as-
sociated with a 7.3-fold increase in the risk of a subsequent
VF [24]. In agreement with this, the results of the present
study show that prior VFs are associated with an increased
incidence of VFs in AS patients. It is important to know
whether the strong relationship between a previous VF and
a new VF is due to BMD or to the abnormal spinal bio-
mechanics associated with the prior fracture; however, thisew vertebral fractures
AS patients without baseline VFs
(n = 268)
-value Odds ratio 95% CI P-value
0.001
0.005 4.8 1.4 to 15.9 0.011
ndylitis spine score; CRP, C-reactive protein.
Table 4 Age-specific prevalence ratio for vertebral
fractures in ankylosing spondylitis patients
Age (years) Age ≥40 years General population SPR (95% CI)






40 to 49 14/69 (33.3%) 26/494 (5.2%)
50 to 59 7/28 (25.0%) 70/840 (8.3%)
60 to 69 3/7 (28.6%) 177/964 (18.4%)
70 to 79 3/4 (75%) 91/386 (30.8%)
Total 27/108 (25%) 364/2684 (13.6%) 3.3 (2.1 to 4.5)
1Data from Shin et al. [16]. VF, vertebral fracture; SPR, standardized
prevalence ratio.
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spective cohort study will be designed to investigate this.
The results of the present study also suggest that ap-
propriate anti-inflammatory therapy may prevent the in-
cidence of new VFs in AS patients with and without
previous VFs. In the case of RA (the most common type
of chronic inflammatory arthritis), CRP levels are associ-
ated with VFs [25]. Previous studies also show that a re-
duction in CRP levels is correlated with increased BMD
in both the hip and lumbar spine in AS patients [26,27].
It is possible that the increase in CRP may lead to a re-
duction in BMD, thereby increasing the risk of VF. Also
CRP levels are associated with disease activity in AS
[28,29]. An increase in CRP levels may be associated
with the aggravation of back pain and stiffness, leading
to increased rigidity. This, in turn, may cause new VFs.
Recent prospective cohort studies show that CRP is an
independent risk factor for VF in the elderly general
population [30,31], and Ishii et al. suggested that com-
posite strength indices show an inverse relationship with
CRP levels [32]. Taken together, CRP levels may predict
the incidence of VF in AS patients and in the elderly
general population. Fracture prevention is indicated in
high-risk AS patients with a previous history of VFs or
with active inflammatory conditions.
In a previous study, radiographic damage has been asso-
ciated with VF in AS. Vosse et al. reported that modified
(m)SASSS correlated with mean wedging at the thoracic
spine and hyperkyphosis [33]. In the current study, uni-
variate analysis revealed an association between SASSS
progression and the incidence of new VF (OR: 2.9, 95%
CI = 1.19 to 7.09; data not shown); however, this did
not reach statistical significance in multivariate analysis.
However, we must point out that Vosse et al. per-
formed a cross-sectional study whereas we performed a
longitudinal study. Therefore, the relationship between
the observed radiographic damage and the prevalence
and incidence of VF may be different. Furthermore, weonly examined the incidence of VF at T12 to L4. Vosse
et al. found no association between mSASSS and VF in
the lumbar spine. Further large prospective studies, in-
cluding both the thoracic and lumbar spine, are needed
to validate the relationship between radiographic dam-
age and the incidence of new VF.
The medical treatment of AS has improved dramatic-
ally over the last few decades. TNF inhibitors markedly
reduce symptoms such as back pain and enthesitis
[1,34,35]; however, it is still unclear whether these new
treatments lead to a reduction in bone complications.
Here, we report the effects of TNF inhibitors on the in-
cidence of morphometric VFs in AS patients. Univariate
analysis showed that treatment with TNF inhibitors led
to a moderate reduction in the incidence of VF; however,
multivariate analysis did not identify a protective effect.
Because our results suggest that increased inflammation
is associated with the risk of VF, the inhibition of inflam-
mation through the administration of TNF inhibitors
has a possibility to prevent new VFs; therefore, the ef-
fects of TNF inhibitors should be studied in a future
randomized control study of AS patients with a high
inflammatory status. Vosse et al. report that NSAIDs
reduce the risk of clinical fracture in AS patients [10].
Continuous use of NSAIDs reduces syndesmophyte for-
mation and prevents progressive rigidity of the spine,
making patients less vulnerable to VF [36]. The effects
of NSAIDs on fracture repair have been demonstrated in
mouse models [37]; however, we did not find that NSAIDS
prevented new VF.
Cooper et al. reported that female AS patients
aged ≥50 years showed a 7.6-fold increase in the risk for
VF when compared with the general population [6]. A re-
cent large retrospective cohort study compared the risk
of clinical VFs in AS patients with that in healthy con-
trols. AS patients had an increased risk of clinical VFs,
with an OR of 3.28 (95% CI = 1.51 to 7.02) [10]. The SPR
of morphometric VF risk identified in the present study
is similar to that of clinical VF.
This study has several limitations. First, we were not
able to investigate the relationship between smoking and
the risk of VF. Smoking is a risk factor for spinal radio-
graphic progression [38] and is associated with VF in AS
patients [7]. Unfortunately, we did not examine smoking
habits in this study due to insufficient information at
baseline. Second, we only assessed fractures from T12 to
L4. Because AS patients also show an increased inci-
dence of thoracic VFs, we may have underestimated the
total incidence in our study population.
Conclusions
We found that the incidence of morphometric VFs in
AS patients was 4.7% at 2 years and 13.6% at 4 years,
and that previous VFs and elevated CRP levels are
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identify the effects of treatment interventions on the pre-
vention of new VFs.
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